Good morning from Times Square! Northwestern Medicine oncologist Ami Shah, MD joins Good Morning America to kick off #BreastCancerAwarenessMonth . Tune in this morning!

Tune in to GMA as I discuss with Ami Shah, MD the latest in breast cancer prevention and treatment. O'Neal Comprehensive Cancer Center at UAB UAB Department of Medicine Northwestern Feinberg School of Medicine

At Dancing with Chicago Celebrities event with Dr. Ami Shah ⁦Ami Shah, MD⁩ of ⁦⁦Lurie Cancer Center⁩ who will compete in a little while on behalf of Northwestern Medicine & ⁦Lurie Cancer Center⁩. I am confident she will win! The event raises funds for breast cancer research.

Brava to our colleague Ami Shah, MD on her discussion with Good Morning America about the research we do that has advanced breast cancer care! #PrecisionMedicine #BreastCancerAwareness

This morning! #Breastcancer oncologist Amy Shah, MD, from Lurie Cancer Center Northwestern Medicine, discusses exciting advances in #breastcancer treatment with Robin Roberts as Good Morning America kicks off #BreastCancerAwarenessMonth

Single-Cells Isolation and Molecular Analysis: Focus on HER2-Low CTCs in #MetastaticBreastCancer
mdpi.com/2072-6694/14/1… Paolo D'Amico
Carolina Reduzzi Lorenzo Gerratana Andrew Davis Marwa Manai WenanQiang youbin zhang Ami Shah, MD G Curigliano MD PhD Massimo Cristofanilli, MD, FACP
#liquidbiopsy #ctcs #Her2 #MBC

Investigating oncogenic signaling pathways in inflammatory metastatic breast cancer (MBC) though ctDNA next-generation sequencing (NGS) #SABCS20

Dr. Rashmi K. Murthy MD, MBE: No OS difference between 1st HP + AI vs H + AI ñ, 60 vs 57 mo (indication chemo allowed).

Very different than cleopatra: 16 mo improvement in OS!

Is it bc post protocol therapy? What proportion in PERTAIN received #pertuzumab in later lines? #SABCS20 #bcsm

How do we make years of ovarian suppression easier?

Any one use q3 mo lupron dosing (lower cost, less visits, especially in a pandemic and for pts busy with life/work/family)
#SABCS20 #RxPonder

✳️If possible, updated results from #DestinyBreast01 trial after 20 mo f-up are even more impressive than those reported on NEJM

👉ORR 61%
👉mPFS 19.4 mo & mDOR 20.8 mo‼️
👉mOS 24 mo in highly pretreated pts

Slightly ⬆️ILD rate than previously reported (15% all grade, 2.7% G5)

Considerations for young pt, HR+ node+ bc
- ABC: TC vs ACT?
- SOFT/TEXT: OS/AI
- #RxPonder : omit chemo?
- potent - fluoropyrimidine?
- #monarche : abema?

tools to tailor therapy—>liquid bx/mrd for breast cancer? #bcsm #SABCS20 Massimo Cristofanilli, MD, FACP Andrew Davis Lorenzo Gerratana

Dr. Li: Prelim analysis, esr1 mutations associated with ctc clusters.
-Potential pharmacological inhibitors that dissociate ctc clusters
-maybe along side a new class of serds w efficacy in esr1 mutations? Looking forward to presentations re these serds #SABCS20 Massimo Cristofanilli, MD, FACP

Looking forward to the presentation tomorrow! Will be great to further tailor recommendations for chemotherapy in post menopausal patients with HR+ breast cancer that is node-positive #SABCS20 #RxPonder

Dr rastogi: monarch-e absolute 3% improvement in distant dfs at 2 years
Looking forward to future data:
- what % Young pts had optimal endocrine therapy (ovarian supp)
- just delaying relapse or truly more cures?
- future: liquid bx to stratify higher risk pts?
#bcsm #SABCS20

With the growing arsenal or (neo)adjuvant options need better strategies for risk-adapted therapy and DTC/mrd/liquid biopsy holds great promise.

Impressive RT de-escalation studies. FAST-forward 5 yr data showing 1 wk RT non inf to 3, should this impact our discussion of omission of radiation vs ET in older breast ca pts? Some may prefer RT alone -Dr. Reshma Jagsi #SABCS2020 #bcsm

virtual #sabcs = flipping between great sessions.

Global screening session: different risks/benefits equation based on resources &pt population

#Tigerlily session: big diff by race in 40-50 yo women in the US.

So how do we better tailor screening rec here to incorporate this?

I